News

XBiotech Halts Clinical Trials for Rheumatoid Arthritis Treatment

XBiotech Halts Clinical Trials for Rheumatoid Arthritis Treatment

XBiotech Halts Clinical Trials for Rheumatoid Arthritis Treatment

XBiotech (NASDAQ: XBIT) has announced a significant pause in its clinical program targeting rheumatological diseases. This decision comes in the wake of findings from a recently completed Phase II study focused on rheumatoid arthritis. Although the study was intended to showcase the potential of Natrunix, the results did not live up to expectations, leading to a careful re-evaluation of the research protocols and methodologies used during the trial.

Understanding the Phase II Study Results

In the Phase II study, approximately 230 participants diagnosed with moderate to severe rheumatoid arthritis received treatment with the candidate drug Natrunix, alongside methotrexate (MTX). The trial was designed to assess the drug's efficacy based on the American College of Rheumatology (ACR) 20 response rate, which measures a 20% improvement in symptoms after 12 weeks. Additionally, the study included an extensive range of evaluations such as pain scores, joint counts, quality of life indicators, and safety assessments, all of which are critical in rheumatological research.

Irregularities Observed During the Study

However, the findings from this research were clouded by several irregularities at some of the highest enrolling clinical sites. Alarmingly, there were instances of subjects being enrolled multiple times, leading to discrepancies in the data collection process. These irregularities have raised significant concerns among researchers about the integrity of the results. While the study did not meet its primary efficacy endpoints, ongoing data analysis is being undertaken to clarify the implications of the findings and to decide the next steps.

Future Plans for Natrunix Research

XBiotech had ambitious plans to expand its research into arthritis and other rheumatological conditions such as ankylosing spondylitis. However, these initiatives are currently on hold as the team seeks to fully understand and validate the implications of the recent study outcomes. Every effort is being made to ensure that future studies are robust and lead to genuine insights into the treatment landscape for patients with rheumatic diseases.

About XBiotech

XBiotech is at the forefront of developing innovative therapeutics based on its proprietary True Human™ antibody technology. This groundbreaking method allows for the creation of candidate drugs, like Natrunix, from individuals with natural immunity against various diseases. The company is situated minutes from the heart of Austin and boasts advanced facilities that include GMP manufacturing, research labs, and clinical operations dedicated to infectious disease research.

Contact Information

For inquiries regarding XBiotech and its ongoing projects, please reach out to:

Wenyi Wei
Email: wwei@xbiotech.com
Phone: 737-207-4600

Frequently Asked Questions

What caused XBiotech to halt its clinical program?

XBiotech halted its clinical program after the Phase II study for rheumatoid arthritis did not meet its primary endpoint and revealed significant irregularities.

What is Natrunix?

Natrunix is a candidate drug developed by XBiotech, designed to be used in combination with methotrexate for treating rheumatoid arthritis.

How many participants were involved in the Phase II study?

A total of 230 participants with moderate to severe rheumatoid arthritis were enrolled in the Phase II study.

What are the next steps for XBiotech?

XBiotech is currently analyzing the results of the Phase II study to determine implications for future rheumatology studies and decide how to proceed.

How can I contact XBiotech for more information?

For more information, you can contact Wenyi Wei via email at wwei@xbiotech.com or by phone at 737-207-4600.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 167

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 125

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 305

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 97

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative DREAM JEANS Enhance Natural Curves with Comfort

Updated Category News Views 194

Stylish Jeans for a Natural Lift In the world of fashion, innovation often leads to surprising breakthroughs that combine style with functionality. One exciting development comes from an inventor who has created a brand-new jean design aimed at enhancing the natural shape of the body. The DREAM JEANS are crafted to provide lift, contour, and shape to the derriere,...

Continue Reading
Swvl Introduces New Contracts and Expands in Saudi Arabia

Updated Category News Views 113

Swvl's New Contracts Signal Growth in Saudi Arabia Swvl Holdings Corp, a leading provider of technology solutions for enterprise and government mobility, has recently made news by finalizing new contracts in Saudi Arabia. These agreements add a remarkable $2.6 million to the company's annual contract value, which accounts for approximately ten percent of Swvl's total...

Continue Reading
Arizona Sonoran Implements New Shareholder Rights Plan

Updated Category News Views 202

Arizona Sonoran Copper Company Announces New Rights Plan Arizona Sonoran Copper Company Inc. (TSX:ASCU | OTCQX:ASCUF) has taken an important step for its shareholders by adopting a new shareholder rights plan effective as of a date in the future. This move is intended to ensure that all shareholders are treated equitably in any future takeover attempts and to guard...

Continue Reading
Champ the Golden Retriever: First Live Mascot of 2026 Games

Updated Category News Views 243

Meet Champ: The Inspiring Live Mascot of the 2026 USA Games As the world prepares for the 2026 Special Olympics USA Games, there's an exciting new addition to the team - Champ, a golden retriever therapy dog. Champ is set to be the first-ever live mascot in the history of these games, embracing the role with an important mission beyond just being a charming face. She is...

Continue Reading
Investors Alert: Important Update on BioAge Labs Safety Issues

Updated Category News Views 147

A Deep Dive into the BioAge Labs Situation Faruqi & Faruqi, LLP is actively assisting investors from BioAge Labs, Inc. (NASDAQ: BIOA) who have experienced losses exceeding $75,000. If you are one of these investors, it is vital to reach out and explore your legal options. Understanding Your Rights Investors who encountered significant losses between critical periods...

Continue Reading